DCPH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.08% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	1.57M
Vidutinė apimtis	2.04M
Rinkos kapitalizacija	2.21B
EPS	$-0.520 ( Q1 \| 2024-05-10 )
Kita pelno data	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.58 (Sector) 42.63 (Industry) 0
ATR14	$0.00600 (0.02%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Brightstar Associates Llc	Buy	48 136	Common Stock
2024-04-22	Brightstar Associates Llc	Sell	48 136	Warrants (right to buy)
2024-02-15	Sherman Matthew L	Buy	17 275	Common Stock
2024-02-16	Sherman Matthew L	Sell	2 615	Common Stock
2024-02-15	Sherman Matthew L	Buy	69 100	Stock Option (Right to Buy)

INSIDER POWER
31.00
Last 99 transactions
Buy: 7 012 970 \| Sell: 3 558 980

Koreliacija (AI algo v.1.1b): Undervalued: 0.08% $25.63 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.56 (weak)

Trumpas: 0.95 (very strong)

Signal:(68.551) Expect same movement, but be aware

Deciphera Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OZEM	1
AGBA	0.95
THCP	0.909
POET	0.893
NTIC	0.888
HIBB	0.874
UAL	0.872
STCN	0.869
NBBK	0.868
HLP	0.857

10 Labiausiai neigiamai susiję koreliacijos
RFAIU	-0.958
ICLK	-0.943
INDH	-0.921
VAXX	-0.9
IIMFX	-0.876
CETX	-0.869
ERNZ	-0.856
IBAC	-0.855
GLYC	-0.85
GRDI	-0.848

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Deciphera Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.35
( neutral )

0.24
( neutral )

0.00
( neutral )

-0.28
( neutral )

Deciphera Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$163.36M
Bruto pelnas:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2023
Pajamos:	$163.36M
Bruto pelnas:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2022
Pajamos:	$134.04M
Bruto pelnas:	$125.27M (93.46 %)
EPS:	$-2.37

FY	2021
Pajamos:	$96.15M
Bruto pelnas:	$93.22M (96.95 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Deciphera Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.